Filing Details
- Accession Number:
- 0000899243-21-025001
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-21 16:31:30
- Reporting Period:
- 2021-06-17
- Accepted Time:
- 2021-06-21 16:31:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1629137 | Global Blood Therapeutics Inc. | GBT | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1574579 | Dawn Svoronos | C/O Global Blood Therapeutics, Inc. 181 Oyster Point Blvd. South San Francisco CA 94080 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-06-17 | 3,037 | $0.00 | 5,293 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-06-18 | 1,609 | $36.54 | 3,684 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2021-06-17 | 3,037 | $0.00 | 3,037 | $0.00 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2021-06-17 | 5,600 | $0.00 | 5,600 | $37.09 |
| Common Stock | Restricted Stock Units | Acquisiton | 2021-06-17 | 3,600 | $0.00 | 3,600 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2021-06-17 | No | 4 | M | Direct | |
| 5,600 | 2031-06-16 | No | 4 | A | Direct | |
| 3,600 | No | 4 | A | Direct |
Footnotes
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2021 to cover the Reporting Person's tax obligations in connection with the vesting of 3,037 shares of Common Stock underlying the Reporting Person's RSUs.
- The RSUs vested in a single installment on June 17, 2021.
- The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2021 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).
- The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).
Billionaire Hedge Funds
